Pharmaceutical combination for use in age-related and / or degenerative diseases
A sub-therapeutic dose combination of metformin and galantamine effectively treats age-related diseases, extending lifespan and healthspan by synergistic action, addressing the limitations of current interventions in human aging.
Patent Information
- Application Number
- JP2024136978
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-06-29
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-07-01
AI Technical Summary
Current interventions have not effectively slowed down the aging process in humans, and there is a lack of synergistic effects when metformin and galantamine are combined at therapeutic doses for treating age-related diseases.
A pharmaceutical combination of biguanides, such as metformin, and acetylcholinesterase inhibitors, like galantamine, is administered at sub-therapeutic doses to achieve synergistic effects in treating age-related diseases, including immune diseases, inflammatory diseases, and neuromuscular disorders.
The combination of metformin and galantamine at sub-therapeutic doses extends lifespan and healthspan, improves muscle function, and reduces symptoms of age-related diseases in both C. elegans and OPA1 mouse models, demonstrating enhanced efficacy over individual use.
Smart Images

Figure 2024161512000004 
Figure 2024161512000005 
Figure 2024161512000006
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical combination used for the treatment, prevention and / or stabilization of age-related and / or degenerative diseases. In particular, said pharmaceutical combination comprises a biguanide and an acetylcholinesterase inhibitor and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof. The present invention also relates to the use of said pharmaceutical combination for the prevention, stabilization and / or reduction of age-related and / or degenerative complaints, and for improving indicators of lifespan and / or healthspan. [Background technology]
[0002] Aging is the gradual loss and deterioration of function at the cellular, tissue, and organ levels, leading to progressive loss of physiological integrity, increased susceptibility to diseases and external stressors, and ultimately death. With the increasing aging population worldwide, the incidence of age-related diseases is expanding year by year. Thus, numerous attempts have been made to not only treat age-related diseases, but also to delay the onset of the complex process of aging. As a result, many aging-related pathways have been identified that can be targeted to extend lifespan and healthspan. For example, there is overwhelming evidence that single gene mutations in nutrient-sensing pathways, such as insulin / insulin-like growth factor (IGF) signaling or mechanistic target of rapamycin (mTOR) signaling pathways, extend lifespan and healthspan in invertebrates. These pathways have also been evaluated in mammalian models, where healthspan and lifespan have been extended by genetic manipulation or drugs. This brings hope for new interventions, including drugs that slow the aging process and delay the appearance of age-related diseases by modulating conserved aging pathways, but unfortunately, so far, except for some symptomatic treatments, there are no known interventions that have been shown to effectively slow the aging process in humans. Ultimately, there is an increasing need and demand for measures to maintain health and slow aging, in addition to medical treatment of existing diseases and disorders.
[0003] Over the past decades, several model organisms have been used to gain more insight into the complex science of aging. Caenorhabditis elegans (C. elegans) is a commonly used model animal organism for the study of aging and age-related diseases, with notable advantages such as a short life cycle, simple experimental manipulation, and abundant genetic resources. In addition, it is the first multicellular organism for which full genome sequencing has been completed, its genome contains two-thirds of human disease-related genes, transgenic disease models can be easily disrupted by GFP labeling and whole-genome RNAi technology, and it is possible to conduct systematic and complete lifelong follow-up studies on degenerative pathologies and potential drugs at the individual level, which is particularly important for the study of aging and age-related diseases. Therefore, the use of C. elegans greatly facilitates the explanation of pathological mechanisms related to aging and the development of active compounds.
[0004] Metformin is widely used and approved as an antidiabetic drug for the treatment of type 2 diabetes. Metformin enhances insulin sensitivity, thereby improving insulin action at the cellular level without affecting insulin secretion. Metformin has also been shown to exert positive effects on several cardiovascular risk factors. Furthermore, metformin has also been shown to target many aging mechanisms. Specifically, in the case of aging, metformin leads to reduced insulin levels, reduced IGF-1 signaling, inhibition of mTOR, inhibition of mitochondrial complex I in the electron transport chain, and reduced endogenous production of reactive oxygen species, activation of AMP-activated kinase (AMPK), and reduced DNA damage. Metformin has also been shown to favorably affect metabolic and cellular processes closely related to the development of age-related conditions such as inflammation, autophagy, and cellular senescence (Non-Patent Document 1). Using the C. elegans model system, the health-promoting and life-prolonging effects of metformin in type 2 diabetes have also been confirmed.
[0005] In human studies, metformin has also been shown to significantly reduce the risk of cancer in diabetic patients (Non-Patent Document 2) and to reduce the risk of coronary artery disease (Non-Patent Document 3). However, both of these effects have been observed when metformin is administered at a fairly high therapeutic dose of at least 1500 mg / day or more. In addition, to date, no synergistic effects of metformin in combination with another compound against age-related diseases have been identified.
[0006] Galantamine, an acetylcholinesterase inhibitor that allosterically regulates nicotinic receptors, is widely known as a drug administered to patients with Alzheimer's disease. In C. elegans, galantamine has been shown to promote cholinergic neurotransmission in a manner similar to that in humans and rescue the paralysis phenotype in a transgenic C. elegans model of Alzheimer's disease (Non-Patent Document 4), but it has been described that galantamine has no effect on locomotor activity, motility, or other forms of decline associated with aging in C. elegans. In humans, galantamine has been shown to significantly reduce deaths due to myocardial infarction (Non-Patent Document 5). In addition, galantamine alleviates inflammation and insulin resistance in subjects with metabolic syndrome (Non-Patent Document 6). However, both of these effects have been observed when galantamine is administered at a fairly high therapeutic dose of at least 24 mg / day or more. Furthermore, no synergistic effects on age-related diseases have been identified when galantamine is combined with another compound.
[0007] In the present invention, the inventors have identified an enhancing and even synergistic effect against age-related diseases using the biguanide metformin in combination with the acetylcholinesterase inhibitor galantamine, notably, this effect was observed even when at least one of the compounds, or both compounds, were administered at their sub-therapeutic doses. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Barzilai et al., Cell Metab. 2016 [Non-Patent Document 2] Fuming et al. Oncol Lett. 2018 [Non-Patent Document 3] Hong et al., Diabetes Care. 2014 [Non-Patent Document 4] Xin et al., Plos One, 2013 [Non-Patent Document 5] Nordstroem et al., 2013 [Non-Patent Document 6] Consolim-Colombo et al.; JCI Insight. 2017 Summary of the Invention [Problem to be solved by the invention]
[0009] The present invention provides a pharmaceutical combination comprising a biguanide and / or its N-oxide, hydrate, pharma- ceutically acceptable salt or solvate and an acetylcholinesterase inhibitor and / or its N-oxide, hydrate, pharma-ceutically acceptable salt or solvate. In the context of the present invention, the pharmaceutical combination is typically used for the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases. Furthermore, the use of the pharmaceutical combination for the prevention, stabilization and / or reduction of age-related and / or degenerative complaints, as well as the use of the pharmaceutical combination for the improvement of indicators of lifespan and / or healthspan, is also disclosed.
[0010] The pharmaceutical combination according to all the different embodiments of the invention comprises a biguanide and / or its N-oxide, hydrate, pharma- ceutically acceptable salt or solvate and an acetylcholinesterase inhibitor and / or its N-oxide, pharma- ceutically acceptable salt or solvate. In a further embodiment, the biguanide is metformin, also called 1,1-dimethylbiguanide or N,N-dimethylbiguanide. In another further embodiment of the invention, the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine. In yet a further embodiment, the pharmaceutical combination according to the invention comprises metformin in combination with galantamine, donepezil, rivastigmine and / or memantine and / or their N-oxide, hydrate, pharma- ceutically acceptable salt or solvate. In yet a further embodiment, the pharmaceutical combination according to the invention comprises metformin and galantamine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates.In yet another embodiment, the pharmaceutical combination according to the invention comprises metformin and donepezil, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates, or metformin and memantine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates, or metformin and rivastigmine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates. In another embodiment, the invention comprises metformin in combination with galantamine and donepezil, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts, or solvates; or metformin in combination with galantamine and memantine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts, or solvates; or metformin in combination with galantamine and rivastigmine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts, or solvates; or metformin in combination with donepezil, rivastigmine and memantine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts, or solvates.In yet further embodiments, the present invention comprises metformin in combination with galantamine, donepezil and memantine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates.
[0011] In a first object of the present invention, the pharmaceutical combination in all its different embodiments as outlined herein above is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing the symptoms of an age-related and / or degenerative disease in a subject. [Means for solving the problem]
[0012] In further embodiments, the age-related and / or degenerative disease is selected from the group comprising immune diseases, inflammatory diseases, endocrine metabolic diseases, diseases of the cardiovascular system, arthropathy, diseases of the digestive system, mitochondrial-related diseases, diseases of the neuromusculoskeletal system, sarcopenia, and frailty.
[0013] In a further preferred embodiment, the age-related and / or degenerative disease is selected from the group consisting of age-related and / or degenerative diseases of the neuromusculoskeletal system, frailty, inflammatory diseases and / or endocrine metabolic disorders. In yet another embodiment, the pharmaceutical combination according to all its embodiments is for use in the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases selected from diseases of the neuromusculoskeletal system and / or frailty. In the context of the present invention, the age-related and / or degenerative diseases of the neuromusculoskeletal system are selected from extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies mainly affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement abnormalities, ataxia, mitochondrial-related neuromusculoskeletal diseases, and sarcopenia.
[0014] Thus, in certain aspects the pharmaceutical combination according to all its embodiments is for use in treating, preventing, stabilizing, delaying the onset and / or reducing symptoms of frailty.
[0015] In another particular aspect, the pharmaceutical combination according to all its embodiments is for use in treating, preventing, stabilizing, delaying the onset and / or reducing the symptoms of sarcopenia.
[0016] In yet another specific aspect, the pharmaceutical combination according to all of its embodiments is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing the severity of extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies primarily affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement abnormalities, or ataxia.
[0017] As already outlined above and in certain embodiments, the pharmaceutical combination according to all of its embodiments is for use in the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of a mitochondrial associated neuromusculoskeletal disorder, said mitochondrial associated neuromusculoskeletal disorder being selected from central core disease and optic atrophy 1 (OPA1) associated disorder, said OPA1 associated disorder being selected from optic atrophy, OPA1 associated hypertension and OPA1 associated atrophy.
[0018] In another aspect the pharmaceutical combination according to all its different embodiments is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing the symptoms of age-related and / or degenerative inflammatory diseases, particularly inflammatory diseases associated with increased cytokine levels.
[0019] In yet another embodiment, the pharmaceutical combination according to all the different embodiments is for use in the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of an age-related and / or degenerative endocrine metabolic disorder, in a further embodiment said age-related and / or degenerative endocrine metabolic disorder is selected from obesity, hypertension, metabolic syndrome, in particular sarcopenic obesity.
[0020] In another aspect, the pharmaceutical combination according to the invention is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing of age-related immune disorders such as age-related decline or dysfunction of immune responses (e.g., response to vaccination), bacterial infections, and viral infections.
[0021] In another aspect, the pharmaceutical combination according to the present invention is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing of age-related endocrine metabolic disorders such as obesity, sarcopenic obesity, metabolic syndrome, type II diabetes and progeria.
[0022] In a further aspect, the pharmaceutical combination according to the invention is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing of age-related diseases of the cardiovascular system, such as atherosclerosis, ischemic heart disease, peripheral arterial disease or stroke.
[0023] In yet another embodiment, the pharmaceutical combination according to the invention is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing of age-related arthropathy, such as rheumatoid arthritis or osteoarthritis.
[0024] In another embodiment, the pharmaceutical combination of the present invention is for use in the treatment, prevention, stabilization, delaying the onset and / or reducing of age-related diseases of the digestive system, such as inflammatory liver disease, gastrointestinal disorders, or constipation.
[0025] As outlined above, it is typical for the present invention that the pharmaceutical combination is used in all its different embodiments for the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases. In a particular aspect of the present invention, the pharmaceutical combination is used in all its different embodiments for the prevention or delay of onset of the age-related and / or degenerative diseases. In another aspect, the pharmaceutical combination is used in all its different embodiments for the treatment of age-related and / or degenerative diseases. In yet a further aspect, the pharmaceutical combination is used in all its different embodiments for the stabilization of age-related and / or degenerative diseases. In yet another aspect, the pharmaceutical combination is used in all its different embodiments for the reduction of symptoms of age-related and / or degenerative diseases. In a further aspect, the age-related and / or degenerative diseases are selected from age-related and / or degenerative diseases of the neuromusculoskeletal system, sarcopenia and / or frailty.
[0026] In a second object, the present invention provides the use of the pharmaceutical combination for the prevention, stabilization and / or reduction of age-related complaints, degenerative dysfunction and / or degenerative complaints. In a particular embodiment, the present invention further provides the use of the pharmaceutical combination for the prevention, stabilization and / or reduction of age-related complaints, degenerative dysfunction and / or degenerative complaints selected from the group including muscle weakness, muscle weakness, neuromuscular degeneration, movement disorder and general weakness. In a further embodiment, the present invention provides the use of the pharmaceutical combination for the prevention, stabilization and / or reduction of age-related complaints, degenerative dysfunction and / or degenerative complaints selected from the group including muscle weakness, muscle weakness, neuromuscular degeneration, movement disorder. In another particular embodiment, in the context of the present invention, the age-related complaint is general weakness.
[0027] In a third object, the present invention provides the use of the pharmaceutical combination for improving indicators of lifespan and / or healthspan.In a further embodiment, the improvement of indicators of lifespan and / or healthspan is selected from the group including: improvement of function in age-related physical disorders, stabilization of the deterioration of age-related physical disorders, reduction or stabilization of age-related complaints, reduction or stabilization of degenerative dysfunction and degenerative complaints, relative to the state of the subject before administration of the pharmaceutical combination or relative to a control population.
[0028] The pharmaceutical combination of use in different embodiments of the invention comprises a biguanide and / or its N-oxide, hydrate, pharma- ceutically acceptable salt or solvate and an acetylcholinesterase inhibitor and / or its N-oxide, pharma- ceutically acceptable salt or solvate. In a further embodiment, the biguanide is metformin, also called 1,1-dimethylbiguanide or N,N-dimethylbiguanide. In another further embodiment of the invention, the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine. In yet a further embodiment, the pharmaceutical combination according to the invention comprises metformin in combination with galantamine, donepezil, rivastigmine and / or memantine and / or their N-oxide, hydrate, pharma- ceutically acceptable salt or solvate. In yet a further embodiment, the pharmaceutical combination according to the invention comprises metformin and galantamine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates.In yet another embodiment, the pharmaceutical combination according to the invention comprises metformin and donepezil, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates, or metformin and rivastigmine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates, or metformin and memantine, and / or their N-oxides, hydrates, pharma- ceutically acceptable salts or solvates.
[0029] In the context of the present invention, age-related complaints, degenerative dysfunctions and / or degenerative complaints include, but are not limited to, muscle weakness, muscle loss, neuromuscular degeneration, movement disorders, immune response disorders, metabolic imbalance, generalized weakness, and frailty. In a particular embodiment, in the context of the present invention, age-related complaints, degenerative dysfunctions and / or degenerative complaints are selected from muscle weakness, muscle loss, neuromuscular degeneration, movement disorders. In another particular embodiment, in the context of the present invention, age-related complaints are generalized weakness.
[0030] In a further embodiment, the present invention provides the use of the pharmaceutical combination as outlined above for the prevention, stabilization of deterioration, delaying the onset and / or reduction of frailty, wherein the reduction in frailty or stabilization of worsening frailty is selected from the group of parameters comprising increased physical strength, stabilization of physical weakness, increased lean body mass, stabilization of weight loss, improved mobility, stabilization of reduced mobility, increased energy, stabilization of reduced energy, increased activity level, stabilization of reduced activity, increased endurance, stabilization of reduced endurance, improved behavioral response to sensory cues, stabilization of behavioral response to sensory cues, reduction or stabilization of one or more inflammatory markers or biomarkers, improved glucose homeostasis and metabolic or catabolic status, improved neurotransmission or neuromuscular transmission, and reduction in one or more biomarkers of coagulation activation, wherein the reduction or stabilization is relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0031] In another further embodiment, the present invention provides a pharmaceutical combination as outlined above for use in the treatment, prevention, stabilization of deterioration, delaying the onset and / or reducing of frailty, wherein the reduction in frailty or stabilization of deterioration of frailty is selected from the group of parameters comprising increased physical strength, stabilization of physical weakness, increased lean body mass, stabilization of weight loss, improved mobility, stabilization of reduced mobility, increased energy, stabilization of reduced energy, increased activity level, stabilization of reduced activity, increased endurance, stabilization of reduced endurance, improved behavioral response to sensory cues, stabilization of behavioral response to sensory cues, reduction or stabilization of one or more inflammatory markers or biomarkers, improved glucose homeostasis and metabolic or catabolic status, improved neurotransmission or neuromuscular transmission, and reduction in one or more biomarkers of coagulation activation, wherein the reduction or stabilization is relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0032] In another embodiment, the present invention provides the use of the pharmaceutical combination as outlined above for improving indicators of longevity and / or healthspan, wherein the improvement in indicators of longevity and / or healthspan is selected from the group comprising improved function in age-related physical disorders, stabilization of the worsening of age-related physical disorders, reduction or stabilization of age-related complaints, reduction or stabilization of degenerative dysfunction and degenerative complaints, relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0033] In another embodiment, improved longevity and / or healthspan indicators in accordance with the present invention include improved one or more parameters selected from the group consisting of cholesterol levels, triglyceride levels, high density lipoprotein levels, low density lipoprotein levels, leptin levels, adiponectin levels, inflammation parameters, chronological versus biological age parameters and blood pressure, immunosenescence, wherein said longevity and / or healthspan indicators are improved relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0034] In yet another embodiment, the present invention provides the use of the pharmaceutical combination disclosed above for improving indicators of longevity and / or healthspan, in particular for enhancing the ability to maintain homeostasis during the application of a stressor and / or for reducing the time required to return to homeostasis after the application of a stressor.
[0035] In all the different embodiments of the invention, the pharmaceutical combination according to the invention can be administered to a subject, in particular a human subject, in a daily therapeutic dose or in a daily sub-therapeutic dose. In yet another embodiment, at least one of the components of the pharmaceutical combination according to the invention is administered to a subject in a sub-therapeutic dose. In another embodiment, at least one of the components of the pharmaceutical combination according to the invention is administered in a therapeutic dose. In yet another embodiment, one of the components of the pharmaceutical combination is administered in a sub-therapeutic dose, whereas the other components are administered in therapeutic doses. In another embodiment, all the components of the pharmaceutical combination according to the invention are administered to a subject in a sub-therapeutic dose.
[0036] In a preferred embodiment, in the pharmaceutical combination, the biguanide or N-oxide, hydrate, pharma- ceutically acceptable salt, or solvate thereof is administered at a sub-therapeutic dose, preferably at a sub-therapeutic dose of up to about 1500 mg / day per subject, more preferably at a sub-therapeutic dose of about 5 mg / day or more per subject, up to about 1500 mg / day per subject, even more preferably at a sub-therapeutic dose of about 5 mg / day to about 1000 mg / day per subject, even more preferably at a sub-therapeutic dose of about 5 mg / day to about 850 mg / day per subject, or about 5 mg / day to about 800 mg / day per subject, or about 5 mg / day to about 750 mg / day per subject, or about 5 mg / day to about 700 mg / day per subject, or about 5 mg / day to about 500 mg / day per subject.
[0037] In another embodiment, the biguanide or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof in a pharmaceutical formulation can also be administered in a therapeutic dose, preferably in a daily therapeutic dose of greater than 1500 mg / day per subject, and even more preferably in a daily therapeutic dose of greater than 1500 mg / day and less than 3000 mg / day per subject.
[0038] In another preferred embodiment, in the pharmaceutical formulation, the acetylcholinesterase inhibitor or its N-oxide, hydrate, pharma- ceutically acceptable salt or solvate is administered at a sub-therapeutic dose, preferably at a sub-therapeutic dose of less than about 16 mg / day per subject, even more preferably at a sub-therapeutic dose of more than about 0.08 mg / day and less than about 16 mg / day per subject, preferably less than about 12 mg / day per subject. In another embodiment, the acetylcholinesterase inhibitor or its N-oxide, hydrate, pharma- ceutically acceptable salt or solvate is administered at a sub-therapeutic dose of more than about 2 mg / day and less than about 16 mg / day per subject, preferably less than about 12 mg / day per subject.
[0039] In another embodiment, in the pharmaceutical combination, the acetylcholinesterase inhibitor or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof is administered in a therapeutic dose, preferably in a daily therapeutic dose of greater than 16 mg / day per subject, and even more preferably in a daily therapeutic dose of between 16 mg / day and 24 mg / day per subject.
[0040] In another preferred embodiment, the pharmaceutical combination according to the invention is a pharmaceutical combination comprising a biguanide, preferably metformin, and an acetylcholinesterase inhibitor selected from galantamine, donepezil, rivastigmine or memantine, wherein both the biguanide and the acetylcholinesterase inhibitor are administered at sub-therapeutic doses. In the above context, the biguanide is administered at a sub-therapeutic daily dose of up to about 1500 mg / day per subject, preferably up to about 1000 mg / day per subject, more preferably at a sub-therapeutic daily dose of more than about 5 mg / day and up to about 1500 mg / day per subject, even more preferably at a sub-therapeutic daily dose of between about 5 mg / day and about 1000 mg / day per subject. Also in the above context, the acetylcholinesterase inhibitor is administered at a sub-therapeutic daily dose of less than about 16 mg / day per subject, even more preferably at a sub-therapeutic daily dose of more than about 0.08 mg / day and less than about 16 mg / day per subject, preferably less than about 12 mg / day per subject. In a further preferred embodiment, the sub-therapeutic daily dose is more than about 2 mg / day and less than about 16 mg / day per subject, preferably less than about 12 mg / day per subject. In a further preferred embodiment, the sub-therapeutic daily dose is between 3 mg / day and 12 mg / day per subject.
[0041] In another aspect of the invention, the pharmaceutical formulations in all the different embodiments of the invention are prepared for oral administration or any other non-invasive administration.
[0042] The pharmaceutical combination according to different embodiments of the invention is further characterized in that the biguanide and the acetylcholinesterase inhibitor, or N-oxides, hydrates, pharma- ceutically acceptable salts or solvates thereof, are formulated separately in pharmaceutical compositions. In a further aspect, the biguanide and the acetylcholinesterase inhibitor, or N-oxides, hydrates, pharma- ceutically acceptable salts or solvates thereof, are administered to a subject simultaneously. Alternatively, the biguanide and the acetylcholinesterase inhibitor, or N-oxides, hydrates, pharma- ceutically acceptable salts or solvates thereof, are administered at different times.
[0043] In another embodiment, the biguanide and the acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof, are formulated into a single pharmaceutical preparation in the pharmaceutical combination of the invention.
[0044] The present invention can be summarized in the following numbered embodiments.
[0045] 1. A pharmaceutical combination for use in treating, preventing, stabilizing, delaying the onset and / or reducing symptoms of an age-related and / or degenerative disease in a subject, comprising: a biguanide, and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; an acetylcholinesterase inhibitor, and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; A pharmaceutical combination comprising:
[0046] 2. The pharmaceutical combination for use according to embodiment 1, wherein the biguanide is metformin.
[0047] 3. The pharmaceutical combination for use according to embodiment 1, wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine, preferably galantamine.
[0048] 4. A pharmaceutical combination for use according to any one of embodiments 1 to 3, wherein the age-related and / or degenerative disease is selected from the group including immune diseases, endocrine and metabolic diseases, circulatory system diseases, arthropathy, digestive system diseases, neuromusculoskeletal diseases, inflammatory diseases, and frailty.
[0049] 5. The pharmaceutical combination for use according to embodiment 4, wherein the immune disease is selected from the group including age-related decline in immune response (response to vaccination), age-related immune dysfunction, bacterial infections, and viral infections.
[0050] 6. The pharmaceutical combination for use according to embodiment 4, wherein the endocrine metabolic disorder is selected from the group comprising obesity, sarcopenic obesity, metabolic syndrome, type II diabetes, progeria, in particular sarcopenic obesity.
[0051] 7. The pharmaceutical combination for use according to embodiment 4, wherein the disease of the circulatory system is selected from the group comprising atherosclerosis, ischemic heart disease, peripheral arterial disease and stroke.
[0052] 8. The pharmaceutical combination for use according to embodiment 4, wherein the arthropathy is selected from the group comprising rheumatoid arthritis and osteoarthritis.
[0053] 9. A pharmaceutical combination for use according to embodiment 4, wherein the disease of the digestive system is selected from the group comprising gastritis, peptic ulcer disease, inflammatory liver disease, gastrointestinal disorders and constipation.
[0054] 10. A pharmaceutical combination for use according to any one of embodiments 1 to 3, wherein the age-related and / or degenerative disease is selected from age-related and / or degenerative diseases of the neuromusculoskeletal system, frailty, inflammatory diseases, and / or endocrine metabolic disorders.
[0055] 11. A pharmaceutical combination for use as described in embodiment 1 for use in the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases of the neuromusculoskeletal system and / or frailty.
[0056] 12. The pharmaceutical combination for use according to embodiment 11, wherein the neuromusculoskeletal disease is selected from the group including extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies mainly affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement abnormalities, ataxia, mitochondrial-related neuromusculoskeletal diseases, and sarcopenia.
[0057] 13. The pharmaceutical combination for use according to embodiment 11, wherein the disease of the neuromusculoskeletal system is selected from the group comprising extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies mainly affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement abnormalities, or ataxia.
[0058] 14. A pharmaceutical combination for use according to embodiment 11, wherein the neuromusculoskeletal disease is sarcopenia.
[0059] 15. A pharmaceutical combination for use according to embodiment 11, which is a disease of the neuromusculoskeletal system.
[0060] 16. A pharmaceutical combination for use according to embodiment 1, wherein the age-related and / or degenerative disease is a mitochondrial-associated neuromusculoskeletal disease, in particular a mitochondrial-associated neuromusculoskeletal disease selected from central core disease and optic atrophy 1 (OPA1)-associated disease.
[0061] 17. Use of a pharmaceutical combination for the prevention, stabilization and / or reduction of age-related and / or degenerative complaints, said pharmaceutical combination comprising: a biguanide, or an N-oxide, hydrate, pharma- ceutically acceptable salt, or solvate thereof; an acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; Use of a pharmaceutical combination comprising:
[0062] 18. Use of a pharmaceutical combination for improving indicators of lifespan and / or healthspan, comprising: a biguanide, or an N-oxide, hydrate, pharma- ceutically acceptable salt, or solvate thereof; an acetylcholinesterase inhibitor, an N-oxide, a hydrate, a pharma- ceutically acceptable salt or a solvate thereof; Use of a pharmaceutical combination comprising:
[0063] 19. Use of the pharmaceutical combination according to embodiment 18, wherein the improvement in indicators of lifespan and / or healthspan is selected from the group comprising: improvement of function in age-related physical disabilities, stabilization of the worsening of age-related physical disabilities, reduction or stabilization of age-related and / or degenerative complaints, relative to the state of the subject before administration of the pharmaceutical combination or relative to a control population.
[0064] 20. Use of the pharmaceutical combination according to embodiment 17 or 19, wherein the age-related and / or degenerative complaints are selected from the group comprising muscle weakness, muscle weakness, neuromuscular degeneration, movement disorders, reduced or impaired immune response, metabolic imbalance, generalized weakness, frailty.
[0065] 21. Use of the pharmaceutical combination according to embodiment 17 or 19, wherein the age-related and / or degenerative complaints are selected from the group comprising muscle weakness, muscle weakness, neuromuscular degeneration, and movement disorders.
[0066] 22. Use of the pharmaceutical combination according to embodiment 17 or 19, in which the age-related and / or degenerative complaint is a generalized feeling of weakness.
[0067] 23. Use of the pharmaceutical combination according to embodiment 20, wherein the reduction in frailty or stabilization of worsening frailty is selected from the group of parameters consisting of increased physical strength, stabilization of decline in physical strength, increased lean body mass, stabilization of weight loss, improved mobility, stabilization of decline in mobility, increased energy, stabilization of decline in energy, increased activity level, stabilization of decline in activity, increased endurance, stabilization of decline in endurance, improved behavioral response to sensory cues, stabilization of behavioral response to sensory cues, reduction or stabilization of one or more inflammatory markers or biomarkers, improvement in glucose homeostasis and metabolic or catabolic status, improvement in neurotransmission or neuromuscular transmission, and reduction in one or more biomarkers of coagulation activation, wherein the reduction or stabilization is relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0068] 24. Use of the pharmaceutical combination according to embodiment 18, wherein the improvement in indicators of lifespan and / or healthspan comprises improvement in one or more parameters selected from the group consisting of cholesterol levels, triglyceride levels, high density lipoprotein levels, low density lipoprotein levels, leptin levels, adiponectin levels, inflammation parameters, chronological age vs. biological age parameters and blood pressure, immunosenescence, wherein said indicators of lifespan and / or healthspan are improved relative to the state of the subject before administration of the pharmaceutical combination or relative to a control population.
[0069] 25. Use of the pharmaceutical combination described in embodiment 18, wherein the improvement in indicators of lifespan and / or healthspan includes an enhanced ability to maintain homeostasis during application of a stressor and / or a shortened time required to return to homeostasis after application of a stressor.
[0070] 26. Use of a pharmaceutical combination according to any one of embodiments 17 to 25, wherein the biguanide is metformin.
[0071] 27. Use of a pharmaceutical combination according to any one of embodiments 17 to 26, wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine.
[0072] 28. A pharmaceutical combination for use according to any one of embodiments 1 to 16, or the use of a pharmaceutical combination according to any one of embodiments 17 to 27, wherein the pharmaceutical combination is prepared for oral administration or any other non-invasive administration.
[0073] 29. The pharmaceutical combination or use of the pharmaceutical combination for use according to any one of the above embodiments, wherein the biguanide and the acetylcholinesterase inhibitor, or the N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof, are formulated separately into a pharmaceutical composition.
[0074] 30. The pharmaceutical combination or use of the pharmaceutical combination for use according to any one of the above embodiments, wherein the biguanide and the acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof, are formulated in a single pharmaceutical formulation.
[0075] 31. The pharmaceutical combination for use or the use of a pharmaceutical combination according to any one of the above embodiments, wherein the biguanide and the acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof, are administered simultaneously.
[0076] 32. The pharmaceutical combination for use or the use of a pharmaceutical combination according to any one of the above embodiments, wherein the biguanide and the acetylcholinesterase inhibitor, or N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof, are administered at different times.
[0077] 33. The pharmaceutical combination for use or use of a pharmaceutical combination according to any one of the above embodiments, wherein the biguanide and acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof, is administered to the subject in a sub-therapeutic dose.
[0078] 34. The use of a pharmaceutical combination or a pharmaceutical combination for use according to any one of the above embodiments, wherein the subject is a human subject.
[0079] With specific reference now to the drawings, it is emphasized that the items shown are exemplary and are intended solely for the purpose of an explanatory discussion of various embodiments of the invention. These drawings are presented to provide what is believed to be the most useful and simplest explanation of the principles and conceptual aspects of the invention. In this regard, no attempt has been made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention. This description, taken together with the drawings, will make apparent to one skilled in the art how some forms of the invention may be practically embodied. [Brief description of the drawings]
[0080] [Figure 1] FIG. 1: Lifespan assay using C. elegans to evaluate the survival benefit of single doses of metformin, galantamine, and the combination of metformin and galantamine. Pooled data from multiple assays measuring survival of C. elegans are shown. Treatment began on day one of adulthood and animals were dosed once. Total lifespan data are shown in Table 1. [Diagram 2] FIG. 1 shows a longevity assay using C. elegans to evaluate the lifespan effect of repeated dosing of metformin, galantamine, and a combination of metformin and galantamine. Treatment began on day 1 of adulthood and animals were repeatedly dosed. Total lifespan data are shown in Table 1. [Diagram 3]A single dose of C. elegans with galantamine and / or metformin positively impacts the mean number of "healthy days" (C) along with multiple locomotor parameters (i.e., mean activity (A) and maximum activity (B)) during aging. The latter is a parameter of healthspan defined as the number of days during which the activity of the animals is higher than 15% of the mean maximum activity of the untreated control condition (within the same assay). In panels A and B, baseline activity (i.e., before blue light stimulation) is shown to the left of the dotted line, while stimulated activity (i.e., after blue light stimulation) is shown to the right of the dotted line. Error bars indicate SEM. Statistical significance levels (and percent change) relative to untreated controls are indicated at the bottom of each chart. Statistical significance relative to "25 mM Met+100 μM Gal" is indicated by an additional line. *pANOVA<0.05, **pANOVA<0.01, ***pANOVA<0.001, NS not significant. [Figure 4] Repeated dosing of C. elegans with galantamine and / or metformin positively affects multiple locomotor and behavioral parameters of post-reproductive adults (mean speed (A), maximum speed (B), running percentage (C), cell occupancy (D)). Error bars indicate SEM. Statistical significance levels (and percent change) relative to untreated controls are indicated at the bottom of each chart. Statistical significance relative to "25 mM Met+100 μM Gal" is indicated by an additional line. *p<0.05, **p<0.01, ***p<0.001, NS not significant. All locomotor activity data are shown in Table 2. [Diagram 5] Combinations of 25 mM Met with the acetylcholinesterase inhibitors Don and Riv, or the acetylcholinesterase inhibitor-like compound Mem, induce a locomotor phenotype very similar to that of 25 mM Met with the acetylcholinesterase inhibitor Gal (mean speed (A), maximum speed (B), running percentage (C), cell occupancy (D)). Statistical significance levels (and percent change) relative to untreated controls are indicated at the bottom of each chart. *p<0.05, NS not significant. Total locomotor activity data are shown in Table 3. [Figure 6]Transcription of the cytoprotective glutathione S-transferase 4 (gst-4) gene is synergistically activated by Met and Gal. Data from an in vivo gene transcription assay in C. elegans. Each circle (biological replicate) consists of thousands of animals. Error bars indicate SEM. Pooled data from three independent assays are shown. Statistical significance levels (and percent change) relative to untreated controls are indicated at the bottom. Statistical significance relative to "25 mM Met+100 μM Gal" is indicated by an additional line. ***pANOVA<0.001, NS not significant. [Figure 7] Adult C. elegans treated with a combination of Met and Gal show improved muscle morphology compared to untreated control animals. (A) Aspect ratio represents a measure of myofilament length and width, while (B) smoothness represents an index of intact myofilament contour. Statistical significance levels (and percent change) relative to the untreated control condition are indicated. *pANOVA<0.05, NS not significant. [Figure 8-1] Muscle-specific Opa1- / - mice treated with a combination of metformin and galantamine maintained fat mass, restored metabolism, and prevented fatty liver. (A) Body weight, (B) lean mass, and (C) fat mass measured in female Opa1f / f (control), Opa1- / - mice supplemented with or without metformin + galantamine after tamoxifen treatment. (D) White adipose tissue (WAT) content in male Opa1f / f, Opa1- / - mice supplemented with or without metformin + galantamine. (E) Food intake. (F-H) In vivo metabolic response to combination treatment. (F) Oxygen consumption (VO2), (G) Carbon dioxide production (VCO2), (H) Energy expenditure, (I) Skeletal muscle IL6 inflammation levels. Data are means ± SEM, female: n = 2–4, male: n = 3, *p < 0.05, **p < 0.01, ****P < 0.0001. [Figure 8-2] Same as above [Figure 8-3] Same as above [Figure 9-1]The combination of both metformin and galantamine improved the physical performance of muscle-specific Opa1- / - mice. (A) Treadmill performance running time and (B) grip strength measured in female Opa1- / - mice treated with or without metformin + galantamine, respectively, 60 and 50 days after tamoxifen treatment. (C-F) Force-frequency curves performed in vivo on gastrocnemius muscle. (C and D) Absolute force and (E and F) maximal specific force generated during tetanus in female and male Opa1- / - mice treated with or without metformin + galantamine, respectively. Data represent mean ± SEM, female: n = 2-4, male: n = 3, *p < 0.05, **p < 0.01. [Figure 9-2] Same as above [Figure 10] The combination of both metformin and galantamine in Opa1- / - mice partially preserved muscle mass. (A-F) Muscle weights of female and male controls (Opa1f / f), Opa1- / - mice supplemented with and without metformin + galantamine treatment, respectively. Quantification of (A,D) tibialis anterior, (B,E) gastrocnemius, (C,F) soleus, (G) muscle fiber number, and (H) denervated NCAM-positive fibers in female controls (OPA1f / f), Opa1- / - mice treated with and without metformin + galantamine. Data are mean ± SEM, female: n=2-4, male: n=3, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0081] The present invention relates to a pharmaceutical combination used for the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases, in particular age-related and / or degenerative diseases of the neuromusculoskeletal system, sarcopenia and / or frailty.
[0082] In the context of the present invention, the term "treat" or "treatment" refers to an action that results in a curative treatment or that alleviates or reduces the severity of a symptom or condition of a disease, or reduces the frequency of occurrence of a disease or disorder. The term includes remitative treatment of a disorder (i.e., a treatment that causes the disorder to go into remission). The term "treat" or "treatment" includes the administration of an agent whereby a disease or condition is at least partially improved or ameliorated, and / or there is some alleviation, alleviation or reduction in at least one clinical symptom, and / or there is a delay in the progression of a condition or disease, and / or there is a prevention or delay in the onset of a condition or disease. Thus, the terms "treat" and "treatment" refer to both prophylactic and therapeutic treatment regimes. The term "treatment" is used interchangeably herein with the term "therapy" and refers to both therapeutic and prophylactic / preventative measures. Those in need of treatment can include individuals already with a particular medical disorder, as well as those who may eventually acquire the disorder (ie, those requiring preventative measures).
[0083] As used herein, "prevention" or "prophylaxis" refers to a method of reducing the risk of developing a disease or condition or symptom. Prevention includes reducing the risk of developing a disease or condition and / or preventing the worsening of symptoms or progression of a disease, or reducing the risk of the worsening of symptoms or progression of a disease or condition.
[0084] As used herein, "stabilization" of symptoms of an age-related or degenerative disease refers to a state in which the number and / or severity of symptoms is neither decreased nor increased.
[0085] As used herein, a "combination" refers to any association between two or more items. The association may be spatial, or may refer to the use of two or more items for a common purpose.
[0086] As used herein, a "composition" refers to any mixture of two or more products or compounds (e.g., agents, modulators, regulators, etc.). A "composition" can be a solution, suspension, liquid, powder or paste, aqueous or non-aqueous formulation, or any combination thereof.
[0087] Thus, the present invention relates to a pharmaceutical combination comprising a biguanide, and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof, and an acetylcholinesterase inhibitor, and / or an N-oxide, hydrate, pharma-ceutically acceptable salt or solvate thereof.
[0088] The N-oxide form is intended to include compounds in which one or several nitrogen atoms have been oxidized to the so-called N-oxide.
[0089] For pharmaceutical use, the compounds of the present invention may be used as free acids or bases, and / or in the form of pharma- ceutically acceptable acid and / or base addition salts (e.g., obtained with non-toxic organic or inorganic acids or bases), in the form of hydrates, solvates and / or complexes, and / or in the form of prodrugs or predrugs, such as esters. As used herein, unless otherwise specified, the term "solvates" includes any combinations that may be formed by the compounds of the present invention and suitable inorganic solvents (e.g., hydrates) or organic solvents (including but not limited to alcohols, ketones, esters, etc.). Such salts, hydrates, solvates, etc. and their preparation will be apparent to those skilled in the art, see, for example, the salts, hydrates, solvates, etc. described in U.S. Pat. Nos. 6,372,778, 6,369,086, 6,369,087, and 6,372,733.
[0090] Pharmaceutically acceptable salts of the compounds according to the invention, i.e., salts in the form of water-, oil-soluble or dispersible products, include the conventional non-toxic salts or the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include alkali metal salts such as ammonium salts, sodium salts and potassium salts, alkaline earth metal salts such as calcium salts and magnesium salts, salts with organic bases such as dicyclohexylamine salts, salts with amino acids such as N-methyl-D-glucamine, arginine, lysine, etc. In addition, basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates such as dimethyl, diethyl, dibutyl; and diamyl sulfate; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides such as benzyl and phenethyl bromides, etc. Other pharmaceutically acceptable salts include sulfates, ethanolates and sulfates.
[0091] Generally, for pharmaceutical use, the compounds of the present invention may be formulated as a medicament or pharmaceutical composition comprising at least one compound of the present invention, at least one pharma- ceutical acceptable carrier, diluent or excipient and / or adjuvant, and, optionally, one or more further pharma- ceutical active compounds.
[0092] By way of non-limiting example, such formulations may be in a form suitable for oral administration, parenteral administration (such as intravenous, intramuscular or subcutaneous injection or intravenous drip), topical administration (including ocular), by inhalation, by skin patch, by implant, by suppository, etc. Such suitable dosage forms may be solid, semi-solid or liquid, depending on the method used for their preparation, and the carriers, diluents and excipients, as well as the mode of administration, and will be apparent to those skilled in the art, again with reference to standard handbooks such as the latest edition of Remington's Pharmaceutical Sciences, as well as, for example, U.S. Pat. Nos. 6,372,778, 6,369,086, 6,369,087 and 6,372,733.
[0093] In the context of the present invention, "age-related disease" refers to an abnormal condition characterized by an organ, part, structure or system of the body being irregular or not functioning properly, which occurs more frequently in older people. Furthermore, as used herein, "degenerative disease" refers to a disease that occurs as a result of a continuous process based on degenerative cellular changes that affects tissues or organs and becomes increasingly worse over time.
[0094] In the context of the present invention, age-related and / or degenerative diseases include, but are not limited to, immune diseases, endocrine and metabolic diseases, circulatory system diseases, arthropathy, digestive system diseases, and neuromusculoskeletal diseases including sarcopenia and frailty. Immune diseases are selected from the group including age-related immune dysfunction, age-related immune response decline (e.g., decreased immune response to vaccination, etc.), bacterial infections, and viral infections. Endocrine and metabolic diseases are selected from the group including obesity, metabolic syndrome, type II diabetes, and progeria. Circulatory system diseases are selected from the group including atherosclerosis, ischemic heart disease, peripheral arterial disease, and stroke. Arthropathy is selected from the group including rheumatoid arthritis and osteoarthritis. Digestive system diseases are selected from the group including gastritis, peptic ulcer disease, inflammatory liver disease, gastrointestinal disorders, and constipation. The neuromusculoskeletal disease is selected from the group including extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies mainly affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases such as amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement abnormalities, ataxia, mitochondrial related diseases, and sarcopenia.
[0095] Diseases of mitochondrial dysfunction have been implicated in neurodegenerative, neoplastic, endocrine and cardiovascular diseases. In the present invention, age-related and / or degenerative mitochondrial-associated diseases are diseases associated with impaired or disrupted mitochondrial function, particularly leading to neuromusculoskeletal dysfunction. The diseases are selected from central core disease and optic atrophy 1 (OPA1)-associated disease. Central core disease is an inherited neuromuscular disorder associated with impaired mitochondrial function. The disease is characterized by an area of reduced oxidative activity running along the long axis of muscle fibers (the "central core") and clinical features of congenital myopathy. OPA1 is located in the inner mitochondrial membrane and helps regulate mitochondrial stability and energy output. Mutations in the OPA1 gene are associated with optic atrophy type 1, a dominantly inherited optic neuropathy that leads to progressive loss of vision and in many cases to blindness.
[0096] As used herein, "sarcopenia" refers to a loss of skeletal muscle mass, quality, and strength. Sarcopenia can lead to frailty, for example, in older adults.
[0097] The term "frailty" refers to an adverse, primarily geriatric, health condition that may include poor functional reserve, accelerated osteoporosis, easy fatigability, reduced muscle strength, high susceptibility to disease, and reduced libido (see, e.g., Bandeen-Roch et al, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61: 262-266, 2006). Frailty may be characterized by meeting three of the following five attributes: unintentional weight loss, muscle weakness, slow walking speed, fatigue, and low physical activity. Further, reduction in frailty or stabilization of worsening frailty is characterized by one or more of the following parameters: increased physical strength, stabilization of physical weakness, increased lean body mass, stabilization of weight loss, improved mobility, stabilization of decreased mobility, increased energy, stabilization of decreased energy, increased activity level, stabilization of decreased activity, increased endurance, stabilization of decreased endurance, improved behavioral response to sensory cues, stabilization of behavioral response to sensory cues, reduction or stabilization of one or more inflammatory markers or biomarkers, improvement in glucose homeostasis and metabolic or catabolic status, improvement in neurotransmission or neuromuscular transmission, and reduction in one or more biomarkers of coagulation activation, wherein the reduction or stabilization is relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
[0098] The present invention further relates to the use of the pharmaceutical combination for the prevention, stabilization and / or reduction of age-related and / or degenerative complaints, which are selected from the group comprising muscle weakness, muscle loss, neuromuscular degeneration, movement disorders, impaired immune response, metabolic imbalance, generalized weakness, frailty.
[0099] As used herein, the term "muscle weakness" refers to a condition in which one or more muscles have reduced strength. The term "muscle strength" refers to the ability of a muscle or muscle group to lengthen or exert force through the skeletal system.
[0100] The term "skeletal muscle" includes skeletal muscle tissue as well as its components, such as skeletal muscle fibers (i.e., fast-twitch or slow-twitch skeletal muscle fibers), myofibers that comprise skeletal muscle fibers, skeletal sarcomeres that comprise myofibers, and the various components of skeletal sarcomeres described above.
[0101] The term "neuromuscular degeneration" refers to any degeneration that impairs any part of the nerves and / or muscles.
[0102] The term "movement disorder" refers to a physical movement disorder and refers to any limitation of independent, purposeful physical movement of the body or one or more limbs of the body.
[0103] In the context of the present invention, "impaired immune response" refers to a decreased cellular or humoral immune response of the body to pathogens, including bacteria and viruses, or cancer.
[0104] As used herein, "metabolic imbalance" refers to any condition associated with elevated levels of plasma glucose or plasma lipids.
[0105] The term "general weakness" refers to a state or condition of weakness that includes symptoms of fatigue, muscle weakness, and limited function.
[0106] As used herein, the term "degenerative complaint" is used for any discomfort or complaint that ultimately leads to a degenerative disease.
[0107] As used herein, the term "inhibiting the onset" or "delaying the onset / development" of a sign of aging means delaying the onset / development, slowing the progression, or reducing the appearance of a sign of aging.
[0108] As used herein, the term "improved performance" refers to any aspect of performance, including, but not limited to, cognitive or physical performance, such as the ability to be independent, to handle some but not necessarily all personal demands, to walk or move, or to interact with others.
[0109] Furthermore, the present invention relates to the use of the pharmaceutical combination according to the present invention to improve indicators of lifespan and / or healthspan.As used herein, the term "lifespan" refers to the maximum lifespan observed in a group of individuals.Alternatively, lifespan refers to the average lifespan expected in a group of individuals.
[0110] The term "healthy lifespan" refers to the period during which an individual meets one or more selected health lifespan indicators. An increase in "healthy lifespan" refers to an extension of health lifespan according to such indicators compared to the health lifespan of a control population. An increase in health lifespan can be measured, for example, by determining the length of time that an individual continues to meet a selected health lifespan indicator(s). Alternatively, an increase in health lifespan can be measured by measuring the degree of improvement in one or more selected health lifespan indicators that correlates with an increase in the length of time that an individual continues to meet the selected health lifespan indicators. Alternatively, health lifespan is the period during which an individual is fully functional and free of chronic disease.
[0111] As used herein, a "control population" refers to a population not treated with the combination of the present invention, whose members have one or more properties and / or conditions of the subject treated with the combination of the present invention. Thus, for example, if a subject is being treated for frailty, the relevant control population may have frailty, and if a subject is being treated for any age-related disease, the relevant control population may have the same age-related disease.
[0112] The term "inflammatory marker" refers to an endogenous condition, often the presence, level, and / or form of a molecule that indicates the presence of inflammation. For example, C-reactive protein (CRP) is an inflammatory marker that has been shown to predict future cardiovascular events in individuals with or without established cardiovascular disease. Inflammatory markers involved in the inflammatory process leading to atherothrombosis include, for example, CRP, adiponectin, monocyte chemotactic protein 1 (MCP-1), CD40 ligand, and lipoprotein-associated phospholipase A(2) (LP-PLA(2)).
[0113] The term "glucose homeostasis" refers to the state of or tendency toward normal (non-pathological) glucose levels, which change appropriately in response to various stimuli. Illustrative indicators of glucose homeostasis include meal-stimulated insulin, glucose, and glucagon-like peptide-1 (GLP-1) levels.
[0114] The term "biomarker of coagulation activation" refers to the presence, level and / or morphology of molecules that indicate the activation of pathways that often lead to the formation of thrombi. Illustrative biomarkers of coagulation activation include, for example, prothrombin fragments 1 and 2, thrombin-antithrombin complex, and fibrin degradation products.
[0115] The term "immunosenescence" refers to the gradual deterioration of the immune system caused by natural aging. The term includes both the ability of a subject to respond to infection and the development of long-term immune memory, particularly through vaccination. For example, immunosenescence includes the decline in response to vaccination in the elderly.
[0116] As used herein, the term "subject" refers to an animal, such as a mammal, that has been or is the subject of treatment, observation, or experiment, e.g., a human. The methods described herein may be useful for both human therapy and veterinary applications. In some embodiments, the subject is a mammal, and in some embodiments, the subject is a human. In a preferred embodiment, the subject is a human subject. In an even more preferred embodiment, the subject is a human subject with an age-related disease, e.g., a human subject over 50 years of age with an age-related disease. In another embodiment, the subject is a human subject with a degenerative disease. In yet another embodiment, the subject is a human subject with an age-related disease and a degenerative disease.
[0117] In all the different embodiments of the invention, the pharmaceutical combination according to the invention can be administered to a subject, in particular a human subject, in a daily therapeutic dose or in a daily sub-therapeutic dose.
[0118] The term "sub-therapeutic dose" as used to describe the amount of biguanide and / or acetylcholinesterase inhibitor refers to a dose of said compound that does not provide the desired therapeutic effect for the disease being treated when administered alone to a patient. This can also be referred to as a "synergistically effective amount," referring to the synergistic effect observed when the compounds are administered together.
[0119] In one embodiment, the amount of the biguanide or acetylcholinesterase inhibitor administered is about 20% less than the therapeutically effective amount. In one embodiment, the amount of the biguanide or acetylcholinesterase inhibitor administered is about 50% less than the therapeutically effective amount. Alternatively, the amount of the biguanide or acetylcholinesterase inhibitor administered is about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 90% less than the therapeutically effective amount.
[0120] For example, a therapeutically effective amount of metformin may be about 2000 mg / day or about 2500 mg / day depending on the patient and / or condition, e.g., body weight. Thus, a total daily sub-therapeutic dose of metformin for a human patient is about 400 mg / day or about 500 mg / day. In another embodiment, a total daily sub-therapeutic dose for a human patient is about 1000 mg / day or about 1250 mg / day.
[0121] Also, for example, the therapeutically effective amount of galantamine may be about 16 mg / day or about 24 mg / day depending on the patient and / or condition, such as body weight.Thus, the total daily sub-therapeutic dose of galantamine for a human patient is about 3.20 mg / day or about 4.80 mg / day.In another embodiment, the total daily sub-therapeutic dose for a human patient is about 8 mg / day or about 12 mg / day.
[0122] The present invention relates to a pharmaceutical combination comprising two different compounds. In this context, various methods of analysis of the pharmacological effects of two (or more) compounds can be utilized and are widely accepted in the field. For example, the term "synergy" refers to the phenomenon in which the magnitude of the effect of the combination is greater than the sum of the individual effects. This definition is very strict, especially considering biological variability, and the highest single agent (HAS) model is applied (Borisy, PNAS, 2013). According to this model, a drug combination is considered synergistic if the effect of the drug combination is significantly greater than the maximum effect of any of the single drugs at the same concentration as the mixture. In the context of the present invention, the synergistic effect of the pharmaceutical combination of the present invention is considered to be relevant and to result in a physiological effect.
[0123] In the experimental part of this study, we used C. elegans, a model organism for studying aging (Carretero et al., Curr Top Med Chem 2017; Kenyon, Nature 2010). Caenorhabditis elegans is a small nematode that has become one of the most intensively studied models in biological research. Since the second half of the 20th century, many fundamental discoveries in life sciences have been made in this nematode, including the discovery of genetic pathways that promote longevity. These pathways have remained relatively unchanged during evolution, allowing their probing in simple invertebrates such as C. elegans.
[0124] Several changes that occur during aging in C. elegans are common to aging in humans, including reduced skin elasticity, loss of muscle mass, loss of muscle integrity, loss of motility, and increased susceptibility to infection. Furthermore, multiple forms of learning and memory decline with age in both C. elegans and mammals. Also, the key genetic and biochemical networks underlying aging and age-related diseases appear to be evolutionarily well conserved. Thus, a suitable model organism such as C. elegans allows a relatively streamlined, high-throughput approach to study and understand these phenomena. Currently, C. elegans is being utilized by researchers worldwide to decipher evolutionarily conserved signaling pathways involved in longevity and to assess the therapeutic potential of interventions aimed at mitigating human aging. In essence, C. elegans combines the experimental advantages of a microorganism (i.e., ease of handling and experimental manipulation) with the advantages of a multicellular context (i.e., modeling complex processes such as aging, pathogenesis, and behavior of an organism).
[0125] The most common method for measuring aging in C. elegans is based on manual detection of worm survival on bacterial agar plates.
[0126] Furthermore, a muscle-specific optic atrophy 1 (OPA1) mouse model was used in the examples shown below. This transgenic mouse model effectively reproduces key pathophysiological aspects of sarcopenia-associated muscle loss and strength and exhibits premature aging (e.g., gray hair, spinal curvature). Specific deletion of OPA1 in skeletal muscle results in mitochondrial dysfunction, increased oxidative stress and inflammation. Furthermore, the OPA1 mouse model is a recognized mouse model for OPA1-associated mitochondrial-related diseases such as optic atrophy and hypertension caused by optic atrophy (Archer, 2013, New Engl J Med 369: 23). EXAMPLES
[0127] Example 1: Caenorhabditis elegans model Materials and Methods Chemical of interest Galantamine hydrobromide (Gal; CAS 1953-04-4, ref. PHR1623), donepezil hydrochloride (Don; CAS 120011-70-3, ref. PHR1584), memantine hydrochloride (Mem; CAS 41100-52-1, ref. PHR1886), and 1,1-dimethylbiguanide hydrochloride (Met; CAS 1115-70-4, ref. D150959) were purchased from Sigma-Aldrich (St. Louis, USA). Rivastigmine tartrate (Riv; CAS 129101-54-8, ref. A18484M) was supplied by Interquim SA (Barcelona, Spain). Stock solutions were prepared in ultrapure Milli-Q water at 3.8 mg / mL (Gal), 416 mg / mL (Don), 216 mg / mL (Mem), and 100 mg / mL (Riv).
[0128] Lifespan assay using Caenorhabditis elegans Wild-type C. elegans N2 strain was obtained from the Caenorhabditis Genetics Center (University of Minnesota, USA) and cultured at 20°C on standard nematode growth medium (NGM) plated with a thin layer of Escherichia coli OP50 unless otherwise stated. C. elegans lifespan was measured similarly to the method described previously1,2. Day 1 of the adult stage was always recorded as day 0. FUdR (5-fluoro-2'-deoxyuridine, Sigma-Aldrich) was used in all lifespan assays to avoid progeny production. Multiple independent assays were performed. A minimum of 100 animals per assay and per condition were used to ensure sufficient statistical power.
[0129] During the "single-dose assay", we used the WorMotel platform for long-term recurrent imaging of C. elegans3. This semi-automated platform allows unbiased longitudinal monitoring of C. elegans aging phenotypes, including quantification of locomotor activity alongside daily measurements of viability. From the onset of adulthood, worms were plated with E. coli HT115(DE3) as a food source and kept in individual wells of screening plates (i.e., microfabricated WorMotel chips prepared as described in3) supplemented with different doses of the corresponding compounds (Table 1). Four replicate screening plates were assayed, with all four tested conditions present on each screening plate (randomized locations). Animals were kept on the same screening plate for the duration of the experiment (30 days). Time of death is determined as the last time with non-zero movement. Note that this imaging platform is not compatible with repeated dosing. We used the statistical software R to construct Kaplan-Meier survival curves, calculate mean and median life spans, and perform all relevant statistical analyses. To compare survival between two conditions, we used the log-rank test (i.e., the survdiff function in the survival package, adjusted for multiple comparisons by the Benjamini-Hochberg method). The corresponding p-value is referred to as plog-rank.
[0130] During the "replicate dosing assay", we followed a robust and technically relatively simple method standard in the field (i.e. manual inspection of age-synchronous population survival on bacteria-coated agar plates2). Briefly, at the onset of adulthood, animals were transferred to standard NGM assay plates (untreated controls) or NGM assay plates supplemented with different doses of the corresponding compound (Table 1). Animals were transferred to fresh standard NGM assay plates or fresh NGM assay plates supplemented with the corresponding compound at different doses three times during the first week and every week thereafter (for a total of 33 days). This dosing schedule complies with the standardized protocol of the Caenorhabditis Intervention Testing Program (CITP)4. Gal was pipetted into the seeded assay plates (at least 2 hours before transferring animals to the assay plates) whereas Met was added to the NGM before autoclaving. The same amount of liquid was added to all plates, including the untreated control and Met condition plates (i.e. mock treatment). Animals that had died by crawling off the assay plates or by internal hatching were examined and removed, and the numbers of live and dead worms were scored every 1-2 days.
[0131] Locomotor activity assay Locomotor activity in C. elegans is characterized by sinusoidal movements (i.e., body bending) that gradually decrease during adulthood. As in other animals, maintenance of coordinated movement is considered a major healthspan parameter5. More specifically, maximum locomotor activity is a good value measure of the overall body condition and health of C. elegans6, while the rate of decline in locomotor activity in mid-life has been shown to predict the longest acceptable lifespan7.
[0132] A. Locomotor Activity Tracking Based on WorMotel (Single Dosage) For each imaging period, the mean and maximum locomotor activity is quantified before and after stimulation with blue light (as described in 3). The resulting activity values are termed "baseline locomotor activity" and "stimulated locomotor activity", respectively. Highly motile animals yield high activity values, whereas slower moving and older animals yield low activity values. The "mean activity" of an animal represents the average of the locomotor activity values detected for that animal over the entire experimental period. The "maximum activity" represents the highest maximum locomotor activity value detected for an animal, regardless of the day of detection. "Healthy days" are defined as the total number of days during which the activity of a live animal is observed to be greater than 15% of the mean maximum activity of the untreated control condition present in the same technical replicate (i.e., chip). An increase in "healthy days" is indicative of an increase in locomotor-based healthspan. Results were analyzed using one-way and two-way ANOVA with Holm-Sidak correction for multiple comparisons in GraphPad Prism software. All corresponding p-values are referred to as pANOVA.
[0133] B. Camera-based Locomotor Activity Tracking (Repeated Dosing) To quantify the locomotor effects in more detail, we took advantage of an automated tracking system for C. elegans that is compatible with standard Petri dishes. The multi-camera tracking system allows for the objective quantification of mean locomotor speed, maximum locomotor speed, and multiple behavioral parameters by path-based image analysis. This system was utilized similarly to Peymen et al.8. Two different assays were performed. In the first assay (Table 2), we assayed the locomotor effects of Gal, Met, and the combination of both compounds. This allowed us to test the synergistic effects between Gal and Met on multiple locomotor parameters. In the second assay (Table 3), we characterized the locomotor effects of the combination of Met with the acetylcholinesterase inhibitor-like compound Mem, alongside the combination of Met with different acetylcholinesterase inhibitors (i.e., Gal, Don, and Riv). That way, we could test whether there was a class effect as a whole (in combination with Met) of acetylcholinesterase inhibitors.
[0134] Synchronized wild-type animals were raised in the presence of the corresponding compound at different doses from L4 stage (i.e. day 0) and FudR until the start of measurements. Animals were re-dosed three times (days 2, 4 and 7) by transferring to fresh compound-treated NGM plates. Before imaging, for each replicate, 20 well-fed live animals were manually transferred from the culture plate to an unseeded NGM plate and transferred 5 min later to another unseeded NGM plate used for imaging. Image acquisition was performed with StreamPix 6 multi-camera software (GigE PRO GP11004M camera with KOWA LM16JC10M lens) at 2 fps for 11 min and constant exposure, after which worms were tracked using custom particle tracking MATLAB® code. For each motile animal (i.e. animals that moved for at least 2 min during the imaging period), behavioral measures "cell occupancy" and "running percentage" were extracted alongside both mean and maximum locomotor speed. The latter represents the percentage of time the animal was detected running (as opposed to pausing or turning). Cell occupancy is a measure that quantifies the spatial search efficiency of the worm. It represents the number of unique cells (1 mm2 squares) visited by the worm during the imaging period. Both behavioral parameters decline during ageing. Experiments were performed in triplicate (or quadruplicate) with 20 worms per replicate and per condition. Results were analyzed using multiple t-tests with Holm-Sidak correction for multiple comparisons in GraphPad Prism software. The corresponding p-value is referred to as p.
[0135] In vivo gene activity assay The transparent body of C. elegans allows for easy and non-invasive measurement of in vivo gene transcription via transgenic fluorescent reporters.9 We measured transcription of the gst-4p::GFP C. elegans GFP reporter to gain insight into the intracellular signaling networks affected by Met and / or Gal. In addition, we tested whether Met and Gal have a synergistic or enhancing effect on activating gst-4 gene transcription.
[0136] The gst-4 gene encodes the cytoprotective and drug metabolizing enzyme glutathione S-transferase 4 (GST-4). gst-4 is a direct target of SKN-1 and an ortholog of the mammalian nuclear factor E2-related factor (Nrf2) protein family, a key transcription factor involved in protection against oxidative and xenobiotic stress. In response to oxidative insults, SKN-1 / Nrf2 is phosphorylated by (among others) PMK-1 / P38 MAPK in the cytoplasm and subsequently translocates to the nucleus to induce the expression of a wide range of antioxidant and detoxifying enzymes, including gst-4. In C. elegans aging studies, transcriptional activation of gst-4 is often used as a readout of SKN-1 activity. Nevertheless, it has also been shown that gst-4 can be transcriptionally activated by the epidermal growth factor (EGF) signaling pathway via EOR-1, a BTB / Zn finger transcription factor similar to mammalian promyelocytic leukemia Zn finger protein (PLZF). Upregulation of detoxifying GST enzymes is a common feature of long-lived C. elegans and has been linked to longevity not only in worms but also across species, including humans.
[0137] GFP fluorescence was quantified by an automated method as previously described11. Briefly, JMET69 animals with the genotype Is[gst-4(1491 bp)::gfp;unc-119(+)];Is[unc-54p::mCherry;unc-119(+)] were grown in the presence and absence of drugs (i.e., Met and / or Gal) on NGM plates seeded with E. coli OP50 from L1 to late L4 stages before being transferred to 96-well plates for fluorescence quantification. Background corrected values are shown. No BCA normalization was used. Mean values were statistically compared by one-way ANOVA with Sidak's multiple comparison test in GraphPad Prism software. The corresponding p-values are referred to as pANOVA.
[0138] Quantification of C. elegans muscle morphology and deterioration The gradual loss of muscle mass and function with age in C. elegans shows a progression very similar to sarcopenia in humans12. Sarcomere is the basic muscle unit and is responsible for muscle contraction. C. elegans sarcomeres, like those in vertebrates, consist of alternating filaments containing myosin and actin. While the myofilaments in the body wall sarcomeres of young animals are organized in parallel symmetric rows, the myofilaments in the sarcomeres of older animals gradually disintegrate into more irregular shapes and orientations.
[0139] By using a transgenic reporter strain in which the myosin heavy chain is fused to a fluorescent GFP (strain RW1596; myo-3p::MYO-3::GFP), the muscle structure of C. elegans can be visualized in vivo. Combined with confocal microscopy and bioinformatics analysis, this provides a qualitative as well as a quantitative readout for the assessment of the organizational level of muscle fibers. An analytical method to quantify muscle degradation has been optimized in the laboratory of Professor Bart Braeckman (UGent; unpublished data). We used this technique to verify whether animals treated with Gal and / or Met exhibit a muscle phenotype similar to younger untreated individuals.
[0140] Synchronized RW1596 animals were grown from the L4 stage (i.e., day 0) onwards in the presence of different doses of the corresponding compound (see Figure 7) and FUdR. Animals were re-dosed once on day 7 by transferring to fresh compound-treated NGM plates. Measurements were performed at late adult stage (i.e., day 14) with at least 30 animals per condition.
[0141] Two morphological measures were extracted for each animal: 'aspect ratio' and 'smoothness'.
[0142] The aspect ratio is a measure of the general dimensions of the sarcomere (i.e., elongated shape). The higher this value, the more elongated the sarcomere. The aspect ratio is calculated as the ratio between the length of the long axis (=length) and the length of the short axis (=width) of the individual myofilaments within the sarcomere. As animals age, the aspect ratio decreases. The smoothness is a measure of the smoothness of the myofilament contour. The lower this value, the more "jagged" and "deformed" the myofilament ends become. The smoothness is expressed in arbitrary units. A value of 1 corresponds to the maximum smoothness observed in myofilaments (i.e., early adulthood), whereas a value of 0 corresponds to the smoothness observed in very old (day 18) control worms. The two conditions were statistically compared by two-tailed Student's t-test using GraphPad Prism software.
[0143] result Synergistic effect of metformin and galantamine combination on lifespan extension Single doses of individual compounds significantly increased the survival rate of C. elegans compared to untreated controls (Met: plog-rank=0.00215; Gal: plog-rank=0.000176) (Figure 1, Table 1). To test for drug synergy, we used the higher single activity (HSA) model. According to this model, a drug combination was considered synergistic if the effect of the combination was significantly greater than the maximum effect of any of the single drugs. Using this model, we revealed drug synergy, since treatment with 25 mM Met and 100 μM Gal resulted in a further increase in survival rate compared to the individual compounds (Met: plog-rank=0.049; Gal: plog-rank=0.0244) (Figure 1).
[0144] For animals repeatedly dosed with Met and Gal, a stronger enhancing effect of the combination of Met and Gal was observed (Figure 2, Table 1). Again, the combination of both drugs (Met and Gal) induced the strongest lifespan extension, with the mean lifespan increasing by 22.1% (plog-rank<1E-6) compared to untreated controls, 12.5% (plog-rank=0.000006) compared to the Gal-treated group, and 8.3% (plog-rank=0.037) compared to the 25 mM Met-treated group. The maximum lifespan of animals treated with the combination of Gal and Met was increased by 29% compared to untreated controls, 23% compared to the Gal-treated group, and 17% compared to the Met-treated group. Overall, the drug combination of Met and Gal induced a significantly greater effect on survival than the maximum effect exerted by any of its individual components (Table 1), indicating a synergistic effect between Met and Gal.
[0145] Table 1. Detailed survival data from longevity assays with C. elegans. Treatment with Met, Gal, and the combination of Met and Gal significantly enhances survival of adult C. elegans. Pooled data from multiple assays are shown. N total number of deaths observed in each condition, SEM standard error of the mean, LS lifespan, MLS mean lifespan, *plog-rank<0.05, **plog-rank<0.01, ***plog-rank<0.001, ****plog-rank<0.0001. Median lifespan (median LS) is defined as the day when 50% of the animals are still alive (i.e., the 50th quantile of the survival curve). Maximum lifespan (max LS) is defined as the day when 10% of the animals are still alive (i.e., the 90th quantile of the survival curve). [Table 1]
[0146] A single dose of C. elegans with a combination of galantamine and metformin positively impacts locomotor activity and locomotor activity-based healthspan Single treatment of C. elegans with individual compounds (Gal and Met) significantly increased multiple locomotor activity parameters at the adult stage (Figure 3). For example, compared to untreated controls, Gal significantly increased the maximum baseline activity by 15% (pANOVA=0.0054), while Met increased the maximum baseline activity by 35% (pANOVA<0.0001). The combination of Gal and Met produced the largest percentage increase in maximum baseline activity, i.e., 41% (pANOVA<0.0001) compared to untreated controls. Furthermore, most locomotor parameters showed a significant improvement effect for animals treated with the combination of Met and Gal compared to at least one single compound treatment (Figure 3). No single compound induced a significantly better effect than the combination of Gal and Met, suggesting an improved efficacy when both Gal and Met are combined.
[0147] Compared to untreated controls, the combination of Gal and Met increased the total number of healthy days (i.e., locomotor activity-based healthspan) by 30%, which was significantly better than the effect observed with Met (+14%, pANOVA=0.037) but not significantly different from the effect observed with Gal (+20%, pANOVA=0.095) (Figure 3C). In summary, locomotor activity during aging and locomotor activity-based healthspan (i.e., the period during life during which animals exhibit a healthy level of muscle function) are significantly enhanced in animals treated with the combination of Met and Gal.
[0148] Repeated dosing of C. elegans with a combination of galantamine and metformin synergistically positively affects locomotor activity and behavioral parameters To gain more insight into the impact on locomotor activity-based healthspan, we quantified four locomotor and behavioral parameters in post-reproductive adult C. elegans worms after repeated dosing with Gal, Met, and their combination. The highest levels of all four parameters were observed for animals treated with a combination of 25 mM Met and 100 μM Gal (i.e., resembling the locomotor phenotype of younger individuals) (Table 2, Figure 4). Animals treated with this combination of Met and Gal showed an increase of 141% (p<0.000001) in mean locomotor speed, 24% (p<0.001) in maximum speed, 46% (p<0.000001) in percentage of time spent running, and 239% (p<0.000001) in cell occupancy compared to untreated controls. Essentially, the age-related decline in these four locomotor activity-based parameters is significantly mitigated by the combination of Met and Gal. Furthermore, a significant synergistic effect was observed between Met and Gal for the parameters "mean locomotor activity speed" and "cell occupancy" compared to single compound treatments (Table 2, Figure 4). Collectively, the results indicate that the combination of Met and Gal can improve locomotor activity-based healthspan more than Met or Gal alone.
[0149] Next, to evaluate the breadth of our compound mixture strategy, we assayed the locomotor activity of C. elegans animals treated with other members of the acetylcholinesterase inhibitor group (always combined with Met). Combinations of 25 mM Met with other acetylcholinesterase inhibitors (i.e., Don and Riv) or acetylcholinesterase inhibitor-like compounds (i.e., Mem) induced a similar locomotor phenotype as the combination of 25 mM Met with the acetylcholinesterase inhibitor Gal (Figure 5, Table 3). Considering all four tested conditions (Table 3), there were essentially no significant differences between the compound treatments (pANOVA=0.25). Of the 16 statistical comparisons (i.e., multiple t-tests) performed, only one was significant, with the combination of Mem with Met resulting in a decrease in maximum locomotor speed (-14.5%; p=0.0036) compared to the condition in which Met was combined with Gal (Table 3). Nevertheless, all 15 other statistical comparisons of locomotor and behavioral parameters were found to be non-significant (Figure 5). Thus, when combined with Met, all acetylcholinesterase inhibitors tested appear to act similarly.
[0150] Table 2. Locomotor activity of mid-adult C. elegans (i.e., day 7 post-reproductive adults) is significantly enhanced after repeated dosing with Gal and Met as well as with their combination. Pooled data of multiple replicates are shown. Significant synergistic effects between Gal and Met (according to HSA model definition) are shown in bold. Significance (relative to untreated control condition) is indicated in the following manner: NS not significant, *p<0.05, **p<0.01, ***p<0.001. N total number of animals tested, SEM standard error of the mean, # number of replicate assays performed. Running percentage represents the percentage of time animals spent running (as opposed to pausing or turning). Cell occupancy indicates the number of unique cells (1 mm2) visited by the worm during the imaging period. Data correspond to Figure 4. [Table 2]
[0151] Table 3. Combining Met with different acetylcholinesterase inhibitors (i.e., Don, Riv, and Gal) or acetylcholinesterase inhibitor-like compounds (i.e., Mem) results in similar locomotor phenotypes. Significance (relative to Met 25+Gal 100 condition) is indicated as follows: NS not significant, *p<0.05. Locomotor activity was quantified on day 7 of adulthood similar to the data presented in Table 2. Pooled data from multiple replicates are shown. N total number of animals tested, SEM standard error of the mean, # number of replicate assays performed. Final concentrations of Gal (100 μM), Don (80.92 μM), Riv (57.12 μM), and Mem (132.2 μM) are based on their maximum daily clinical doses. Data correspond to Figure 5. [Table 3]
[0152] Transcription of glutathione S-transferase 4 is synergistically increased by Gal and Met We assayed glutathione S-transferase 4 (gst-4) transcript levels in age-synchronized C. elegans populations after drug treatment. As expected from literature,14 animals treated with Met showed significantly higher gst-4 transcript levels (+26%, pANOVA<0.0001, FIG. 6) compared to untreated controls. Treatment with 100 μM Gal alone did not induce a significant increase in gst-4 transcription (+9%, pANOVA=0.37). However, the combination of 25 mM Met and 100 μM Gal induced the strongest activation of gst-4 transcription. The fluorescent signal was increased by 62% compared to 100 μM Gal (pANOVA<0.0001) and 28% compared to treatment with 25 mM Met alone (pANOVA<0.0001). Thus, we found that Gal and Met act synergistically to activate gst-4 transcription. This effect was observed very consistently and robustly in additional independent assays, both in the presence and absence of oxidative stress (data not shown). Activation of gst-4 indicates activation of pro-longevity transcription factors Nrf2 / SKN-1 and / or PLZF / EOR-1, along with enhanced protection (detoxification) against oxidative stress and xenobiotics. As mentioned above, upregulation of GST enzymes is associated with longevity in multiple species (including humans) and is a common feature of long-lived C. elegans. Thus, synergistic activation of gst-4 is consistent with our previous observations of the synergistic effect between Gal and Met on longevity. Therefore, because gst-4 activation protects against oxidative stress, we investigated the effect of the combination of Gal and Met on stress resistance to heat and oxidative stress using the label-free automated survival scoring method (FLASS), a method that automates survival assays to determine the median time to death using death-associated fluorescence, as previously described15.
[0153] Muscle morphology of C. elegans is improved by the combination of Gal and Met C. elegans treated with a combination of Gal and Met show quantitative and qualitative improvements in muscle morphology at late adulthood compared to animals in untreated control condition (Figures 7A and 7B). Compared to untreated controls, C. elegans treated with a combination of 25 mM Met and 100 μM Gal showed a significant increase in the aspect ratio of sarcomeres (+7.7%, p=0.045, Figure 7A). Essentially, the general dimensions (i.e., aspect ratio) of the sarcomeres of these animals resemble those of younger individuals. Treatment with 25 mM Met alone or 100 μM Gal alone did not cause a significant increase in the aspect ratio (Figure 7A).
[0154] Another morphological muscle measure quantified was the smoothness of myofilament contours. Compared to untreated control conditions, we observed a 55% increase in the smoothness of myofilament contours in animals treated with a combination of 25 mM Met and 100 μM Gal (FIG. 7B). However, we observed only a trend (p=0.076), likely due to the greater biological variability of this parameter. Nevertheless, representative microscopic images indicated that myofilaments within the sarcomeres of animals treated with a combination of Gal and Met had a more regular shape and orientation than those of untreated animals. More specifically, in contrast to untreated animals, where myofilaments tend to have a somewhat irregular shape and orientation, myofilaments in animals treated with a combination of Gal and Met tend to be organized in a parallel symmetry. This suggests improved muscle function in animals treated with a combination of Gal and Met, and is consistent with our previous observations of enhanced locomotor speed in these animals (see above).
[0155] Example 2: Mouse model Introduction Based on evidence that metformin and galantamine components target known pathways involved in aging and frailty, we investigated the effect of this combination on global changes in aging parameters, alongside sarcopenia and muscle strength in the muscle-specific optic atrophy 1 (OPA1) mouse model. This transgenic mouse model effectively recapitulates key pathophysiological aspects of sarcopenia-associated muscle mass and strength loss and displays premature aging (e.g., gray hair, spinal curvature). 16 Specific deletion of OPA1 in skeletal muscle results in mitochondrial dysfunction, increased oxidative stress and inflammation.
[0156] Materials and Methods OPA1 Mouse Model The generation and characterization of Opa1- / - mice have been described in detail elsewhere.16,17 Inducible muscle-specific deletion of OPA1 was obtained by crossing the Opa1fl / fl line with mice carrying Cre-ER driven by the human skeletal actin promoter (HSA). Tamoxifen-induced CreLoxP recombination was activated by oral administration of tamoxifen-containing chow (Tam400 / Cre ER Harlan) provided ad libitum for 5 weeks. Animals were given 1 mg tamoxifen per day with food intake as indicated. Experiments were performed in both female and male mice.
[0157] Diet Muscle-specific OPA1 knockout mice were fed chow (Standard Diet Certificate from Mucedola SRL) or chow supplemented with both metformin and galantamine. The combination was formulated to provide a daily dose of 2.5 mg galantamine and 410 mg metformin per kg body weight. The study diet was purchased from Mucedola SRL.
[0158] Preclinical testing of body composition and energy Changes in body composition occur throughout the human lifespan: overall, early old age is associated with a gradual increase in fat mass accompanied by a decrease in lean body mass and bone density, and in later stages of life, humans begin to lose weight, especially in adipose stores.
[0159] Weight and body composition Body weight was monitored weekly or biweekly. Measurements of lean and fat mass in live mice were assessed by EchoMRI-100 (EchoMRI, Houston, TX, USA).
[0160] Metabolic assessment The metabolic rate of the mice was assessed by indirect calorimetry using the PhenoMaster metabolic cage system (TSE, Berlin, Germany), which provides direct measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2). Based on these parameters, energy expenditure was calculated.18 In addition, food intake was monitored.
[0161] Preclinical studies on neuromuscular function and performance Neuromuscular function and performance are important clinical outcomes in assessing the overall health of older adults because they are highly associated with adverse health outcomes such as falls, depression, disability, and mortality.
[0162] Physical Performance Functional decline among the elderly is often associated with reduced motor and cognitive abilities, as well as substantial morbidity, and is considered an important determinant of health in older adults. In mice, a comprehensive test was developed to assess behavioral outcomes in aging mice.
[0163] Treadmill The concentric training protocol consisted of treadmill (Biological Instruments, LE 8710 Panlab Technology 2B) running at 13 cm / s with a decrement constant of 5° until exhaustion. Total running time was recorded for each mouse.
[0164] Grip strength Grip strength was measured by having the mouse grasp a grid and then pulling the mouse by the tail and recording the latency to release.
[0165] In vivo force measurements were performed in live animals using a 305B muscle lever system (Aurora Scientific, Ontario, Canada) as previously described. Briefly, the force / frequency protocol consisted of trains of increasing frequency stimuli (single pulses, 20 Hz, 40 Hz, 55 Hz, 75 Hz, 100 Hz, and 150 Hz). Each stimulus was administered for more than 30 seconds after the last, with applied voltages ranging from 4 V to 6 V, the duration of each train set to 200 ms, and the duration of each single pulse set to 200 ms.
[0166] Collection of muscle tissue, liver and white adipose tissue Sixty-seven days after induction, mice were sacrificed and muscles (gastrocnemius, tibialis anterior, soleus) were harvested using standardized dissection techniques. Muscle tissue was trimmed of excess fat and connective tissue, weighed on an analytical balance, and collected for further analysis. Muscle tissue was saved for histology and RNA. Liver was collected and saved for histology. White adipose tissue was collected and weighed using an analytical balance.
[0167] Gene expression Total RNA was isolated from muscle using TRIzol (Invitrogen). Complementary DNA was generated using SuperScript III reverse transcriptase (Invitrogen). Gene expression was determined by 16qPCR as described. Quantitative PCR was performed with the following primers: IL6Fw: TAGTCCTTCCTACCCCAATTTCC, IL6Rv: TTGGTCCTTAGCCACTCCTTC GAPDHFw: CACCATCTTCCAGGAGCGAG, GAPDHRv: CCTTCTCCATGGTGGTGAAGAC.
[0168] Histology and immunofluorescence Frozen sections of gastrocnemius and liver were stained for succinate dehydrogenase (SDH) and Oil red O staining, respectively. The total number of gastrocnemius muscle fibers was calculated from the entire hindlimb cross section based on the assembled mosaic images (magnification ×20). For immunostaining, an antibody against NCAM (1:200 dilution in blocking buffer, Millipore, St. Louis, MO) was used. WGA conjugated to Cy3 was used to identify the myofiber membrane. Images were captured using a Leica DFC300-FX digital charge-coupled device camera and Leica DC Viewer software.
[0169] Statistical methods and definition of synergy All data are presented as mean ± SEM. Comparisons between two groups were performed by two-tailed Student's t-test. For statistical analysis of group differences, we performed one-way ANOVA with appropriate correction for multiple comparisons (Tukey's multiple comparison test, GraphPad Prism software). Repeated measures ANOVA was used to assess significant changes over time between two (or more) groups. A p-value of less than 0.05 was considered significant.
[0170] result Muscle-specific Opa1- / - mice treated with a combination of metformin and galantamine maintained fat mass, restored metabolism, and prevented hepatic steatosis Treatment with a combination of metformin and galantamine did not affect the body weight (Figure 8A) and lean mass (Figure 8B) of female Opa1- / - mice. However, fat mass was preserved in treated aged female Opa1- / - mice (Figure 8C), which has been associated with increased survival in rodent and human studies20,21,22. In parallel, treated male Opa1- / - mice were partially prevented from losing white adipose tissue (Figure 8D). Treated female Opa1- / - mice had increased fat mass compared to untreated Opa1- / - mice, even though this group consumed the same amount of calories (Figure 8E). We next investigated the relationship between body weight and metabolic rate by assessing in vivo metabolism using the PhenoMaster metabolic cage system. Indirect calorimetry revealed that the combination of galantamine and metformin normalized both oxygen consumption and carbon dioxide production in female Opa1- / - mice, especially during the light phase, relative to control mice (Figure 8F and Figure 8G). In parallel, treated female Opa1- / - mice had increased energy expenditure compared to untreated Opa1- / - mice, despite increased fat mass (Figure 8H). Thus, the increased fat mass observed in treated Opa1- / - mice cannot be explained by food intake or energy expenditure. These data suggest that combined treatment with galantamine and metformin corrects the extreme starvation phenotype observed in untreated Opa1- / - mice. Next, Oil red O staining was performed to assess hepatic steatosis in these mice. Untreated female Opa1- / - mice showed hepatic steatosis, which was completely prevented in treated Opa1- / - mice. Muscle expression levels of IL6 in female OPA1- / - treated mice were normalized to control levels, indicating reduced inflammation (Figure 8I).
[0171] Combination of metformin and galantamine improved physical performance in muscle-specific Opa1- / - mice Next, we determined whether physical performance, an important healthspan marker, was preserved in treated Opal- / - mice. To confirm the physical health of these animals, we included treadmill, grip, and force measurements. Treated female Opal- / - mice ran three times as much as untreated Opal- / - mice (Figure 9A). Furthermore, a significant effect of the combined treatment was observed in grip strength (Figure 9B). Treatment showed an increase in absolute force (Figure 9C) and maximum specific force (Figure 9E) generated during tetanus in treated female Opal- / - mice, but this effect was not significant. The lack of significance in females is likely a result of insufficient numbers and greater biological variability. However, a significant increase in absolute force and maximum specific force was observed in female Opal- / - treated mice compared to untreated Opal- / - mice (Figures 9D-F), indicating reduced muscle weakness in treated Opal- / - mice. Overall, these studies indicate that the combination of galantamine and metformin improved the general condition of Opa1− / − mice, which was associated with lower all-cause and cardiovascular mortality23.
[0172] Combination of metformin and galantamine partially preserved muscle mass in Opa1- / - mice Muscles of both untreated and treated Opa1- / - mice were smaller than those of control mice, both in females (Figures 10A-C) and males (Figures 10D-F). In females, the tibialis anterior, a glycolytic type II (fast twitch) fiber, was partially preserved in treated Opa1- / - mice (Figure 10A), whereas in males, the gastrocnemius and soleus were partially rescued in treated Opa1- / - mice (Figure 10E). This is an important finding since age-related muscle atrophy is higher in glycolytic muscles (tibialis anterior, gastrocnemius) compared to oxidative muscles (e.g., soleus). Succinate dehydrogenase (SDH) staining was increased in female Opa1- / - untreated mice compared to control and Opa1- / - untreated animals, indicating increased oxidative metabolism. However, regions of myofiber type IIA cytoplasm were devoid of mitochondria in untreated Opa1- / - mice (histopathology data at time of filing), a pattern of localization resembling central core disease, which was maintained in treated Opa1- / - mice. Consistent with SDH staining, an increase in type IIA fibers was observed in untreated Opa1- / - animals compared to control and treated Opa1- / - mice (Figure 10G). Next, we examined the expression of neural cell adhesion molecule (NCAM), a molecule that is enriched in the postsynaptic membrane of the neuromuscular junction (NMJ) but is largely absent in adult myofibers. However, after loss of innervation, NCAM is re-expressed along the entire myofiber. Importantly, loss of myofiber innervation, which occurs during normal aging and coincides with accelerated muscle atrophy, was partially prevented in treated female Opa1- / - mice, as indicated by a decrease in NCAM-positive fibers (Figure 10H). Additionally, bone health will be assessed in these mice. Micro-CT will assess several parameters, including trabecular bone volume, trabecular connectivity, and trabecular bone density and cortical thickness.
[0173] Opa1- / - mice are further treated with the individual components galantamine and metformin separately and subjected to the same analysis as above.
[0174] Physiological, metabolic, and functional health trajectories longitudinally with metformin and galantamine combination The effect of the drug combination (metformin + galantamine) on physiological, metabolic, and functional health trajectories was measured throughout the lifespan of two strains of mice, both male and female (called the Longitudinal Study of Aging in Mice-2 (SLAM-2)). The study setup was based on the SLAM-1 study at the National Institute on Aging (NIH, USA), testing for the same aging and age-related phenotypes, but without intervention. SLAM-2 will be a very extensive study, starting with measurements in mice at 12 months of age. At different endpoints throughout the lifespan, various tests will be performed, focusing mainly on four key aging phenotypes: metabolic (e.g., diabetes, NAFLD, metabolic syndrome), neuromuscular (e.g., sarcopenia, osteoporosis, NMJ stability), cardiovascular (e.g., heart failure), and cognitive (e.g., Alzheimer's), areas that are highly relevant to human health, as they are the main causes of disability, mortality, and morbidity. The SLAM-2 results, compared to the baseline results from SLAM-1, will reveal how the trajectories of biological and physiological parameters are altered by the intervention of compounds known to positively impact healthy aging.
[0175] Additionally, separate studies will examine the healthspan and lifespan effects of both individual compounds as well as combinations of drugs. Comprehensive studies similar to those described in SLAM-2 will be conducted longitudinally, at regular weekly and monthly intervals, over the lifespan of the animals.
[0176] Combination of metformin and galantamine promotes improved recovery In parallel with the non-stressed studies, the effect of the combination of metformin and galantamine is examined in the context of stressed (resilience) models. Three of the more common clinical diseases associated with human aging are obesity-related type II diabetes (induced by overnutrition), sarcopenia (prolonged bed rest) and neuromuscular junction instability (trauma, surgery). Three well-established and time-efficient mouse models that can be used to examine the combination of both these complications + / - metformin and galantamine are (I) high-fat diet (HFD)-fed mice, (II) hindlimb suspension, and (III) sciatic nerve crush or section, respectively. In the context of these models, a panel of standardized short-term studies is performed in young and middle-aged mice to determine the effectiveness of the combination of metformin and galantamine in promoting improved resilience.
[0177] Example 3: Human Studies A. A proof-of-concept study in sarcopenic obese patients This exploratory proof-of-concept study is designed to assess to what extent a combination of metformin and galantamine has a positive effect on sarcopenic parameters of muscle mass and strength in sarcopenic obese patients. It is also intended to assess the effect of different dosages of metformin and galantamine on the parameters assessed, including biomarkers of aging. The study is a 24-week randomized, double-blind, placebo-controlled proof-of-concept study consisting of three consecutive 8-week treatment periods at three ascending dose levels.
[0178] Metformin can be provided as an immediate release, extended release, delayed release or controlled release formulation and can be provided in daily dosages of 250 mg (dose level 1), 500 mg (dose level 2) and 1000 mg (dose level 3). Galantamine can be provided as an immediate release or extended release formulation and can be provided in daily dosages of 3 mg (dose level 1), 6 mg (dose level 2) and 12 mg (dose level 3). Combinations of metformin and galantamine can be provided as fixed combinations, for example, 250 mg metformin and 3 mg galantamine (dose level 1), 500 mg metformin and 6 mg galantamine (dose level 2) and 1000 mg metformin and 12 mg galantamine (dose level 3). Matching placebo formulations are provided.
[0179] B. A proof-of-concept study in sarcopenic patients undergoing total hip arthroplasty This exploratory proof-of-concept study is designed to assess to what extent a combination of metformin and galantamine has a positive effect on the sarcopenic parameters of muscle mass and strength in sarcopenic patients scheduled for total hip arthroplasty (THA). It is also designed to assess whether and to what extent patients treated with a combination of metformin and galantamine experience better functional outcomes following THA. The study is a 24-week randomized, double-blind, placebo-controlled, exploratory proof-of-concept study consisting of a 12-week treatment period prior to surgery and a 12-week treatment period following surgery.
[0180] Combinations of metformin and galantamine are provided as fixed combinations, for example, 250 mg metformin and 3 mg galantamine (dose level 1), 500 mg metformin and 6 mg galantamine (dose level 2), and 1000 mg metformin and 12 mg galantamine (dose level 3). Matching placebo formulations are provided. Treatments are partly pre-operative and partly post-operative. [Explanation of symbols]
[0181] Drawing translation Figure 1 Survival (%) Survival rate (%) Untreated control Adult age (days) Figure 2 Survival (%) Survival rate (%) Untreated control Adult age (days) Figure 3 A Mean daily activity per worm ± SEM (pixels moved) Untreated B Maximal activity detected for each worm ± SEM (pixels moved) Untreated C Absolute number of healthy days ± SEM Untreated Figure 4 A Mean speed Untreated B Maximal speed Untreated C Fraction of time spent running Untreated D Cell occupancy (unique 1 mm2 areas visited ± SEM) Untreated Figure 5 A Mean speed B Maximal speed C Fraction of time spent running D Cell occupancy (unique 1 mm2 areas visited ± SEM) Figure 6 Fluorescence intensity (au) ± SEM Fluorescence intensity (au) ± SEM background-corrected Untreated Figure 7 A length of major axis / length of minor axis Untreated B (ranging from 0 to 1) Untreated Figure 8 A Body weight (%) Days of treatment Days of treatment B Lean mass (%) Lean mass (%) Days of treatment Days of treatment C Fat mass (%) Fat mass (%) Days of treatment Days of treatment Opa1- / - treated Opa1- / - treated D Opa1- / - treated Opa1- / - treated E Food intake (g / d) Food intake (g / d) Opa1- / - treated Opa1- / - treated F VO2 ml / h / kg of lean mass VO2 ml / h / kg of lean mass Time (h) Time (h) Opa1- / - treated Opa1- / - treated G VCO2 ml / h / kg of lean mass VCO2 ml / h / kg of lean mass Time (h) Time (h) Opa1- / - treated Opa1- / - treated H Energy expenditure kcal / h / kg of lean mass Energy expenditure kcal / h / kg of lean mass Time (h) Time (h) Opa1- / - treated Opa1- / - treated I Fold induction Fold induction Opa1- / - treated Opa1- / - treated Figure 9 A Time (min) Opa1- / - treated Opa1- / - treatment B Time (sec) Time (sec) Opa1- / - treated Opa1- / - treatment C Force (N) Force (N) Freq (Hz) Frequency (Hz) Opa1- / - treated Opa1- / - treatment D Force (N) Force (N) Freq (Hz) Frequency (Hz) Opa1- / - treated Opa1- / - treatment E Normalized force (N / kg) Freq (Hz) Frequency (Hz) Opa1- / - treated Opa1- / - treatment F Normalized force (N / kg) Freq (Hz) Frequency (Hz) Opa1- / - treated Opa1- / - treatment Figure 10 A~F Muscle weight (mg) Opa1- / - treated Opa1- / - treatment G Type IIA fibers (% of control) Opa1- / - treated Opa1- / - treatment H NCAM positive fibers NCAM-positive fibers (% of control) (% of control) Opa1- / - treated Opa1- / - treated
[0182] Cited references 1. De Haes, W. et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc. Natl. Acad. Sci. 111, E2501~E2509 (2014). 2. Wilkinson, D. S., Taylor, R. C. & Dillin, A. Analysis of aging in Caenorhabditis elegans. Methods Cell Biol. 107, 353~381 (2012). 3. Churgin, M. A. et al. Longitudinal imaging of Caenorhabditis elegans in a microfabricated device reveals variation in behavioral decline during aging. Elife 6, (2017). 4. Lucanic, M. et al. Standardized Protocols from the Caenorhabditis Intervention Testing Program 2013-2016: Conditions and Assays used for Quantifying the Development, Fertility and Lifespan of Hermaphroditic Caenorhabditis Strains. Protoc. Exch. (2017). 5. Keith, S. A., Amrit, F. R. G., Ratnappan, R. & Ghazi, A. The C. elegans healthspan and stress-resistance assay toolkit. Methods 68, 476~486 (2014). 6. Hahm, J.-H. et al. C. elegans maximum velocity correlates with healthspan and is maintained in worms with an insulin receptor mutation. Nat. Commun. 6, 8919 (2015). 7. Hsu, A.-L., Feng, Z., Hsieh, M.-Y. & Xu, X. Z. S. Identification by machine vision of the rate of motor activity decline as a lifespan predictor in C. elegans. Neurobiol. Aging 30, 1498~1503 (2009). 8. Peymen, K. et al. Myoinhibitory peptide signaling modulates aversive gustatory learning in Caenorhabditis elegans. PLOS Genet. 15, e1007945 (2019). 9. Dues, D. J. et al. Aging causes decreased resistance to multiple stresses and a failure to activate specific stress response pathways. Aging (Albany. NY). 8, 777~795 (2016). 10. McElwee, J. J. et al. Evolutionary conservation of regulated longevity assurance mechanisms. Genome Biol. 8, R132 (2007). 11. Detienne, G., Van de Walle, P., De Haes, W., Schoofs, L. & Temmerman, L. SKN-1-independent transcriptional activation of glutathione S-transferase 4 (GST-4) by EGF signaling. Worm 5, e1230585 (2016). 12. Herndon, L. A. et al. Stochastic and genetic factors influence tissue-specific decline in ageing C. Elegans. Nature (2002). 13. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. 100, 7977~7982 (2003). 14. Cabreiro, F. et al. Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism. Cell 153, 228~239 (2013). 15. Benedetto, A. et al. LFASS: Label-free automated survival scoring for high-throughput nematode assays. Aging Cell in press (2019). 16. Tezze, C. et al. Age-Associated Loss of OPA1 in Muscle Impacts Muscle Mass, Metabolic Homeostasis, Systemic Inflammation, and Epithelial Senescence. Cell Metab. 25, 1374~1389.e6 (2017). 17. Cogliati, S. et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 155, 160~171 (2013). 18. Weir, J. B. de V. New methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 109, 1~9 (1949). 19. Blaauw, B. et al. Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet. 17, 3686~3696 (2008). 20. Mitchell, S. J. et al. Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice. Cell Metab. 23, 1093~1112 (2016). 21. Liao, C. Y. et al. Fat maintenance is a predictor of the murine lifespan response to dietary restriction. Aging Cell 10, 629~639 (2011). 22. Flegal KM, Kit BK, Orpana H, G. B. Association of all-cause mortality with overweight and obesity using standard body mass index categories. J. Am. Med. Assoc. 97, 3855~63 (2013). 23. Kokkinos, P. Physical Activity, Health Benefits, and Mortality Risk. ISRN Cardiol. 2012, 1~14 (2012).
Claims
1. 1. A pharmaceutical combination for use in treating, preventing, stabilizing, delaying the onset of and / or reducing the symptoms of an age-related and / or degenerative disease in a subject, said pharmaceutical combination comprising: a biguanide, and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; an acetylcholinesterase inhibitor, and / or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; Including, The pharmaceutical combination, wherein the age-related disease and / or degenerative disease is a neuromusculoskeletal disease, frailty, an inflammatory disease, and / or an endocrine metabolic disorder.
2. 2. The pharmaceutical combination according to claim 1, for use in the treatment, prevention, stabilization, delay of onset and / or reduction of symptoms of age-related and / or degenerative diseases of the neuromusculoskeletal system and / or frailty.
3. 3. The pharmaceutical combination for use according to claim 1 or 2, wherein the age-related and / or degenerative disease of the neuromusculoskeletal system is selected from the group including extrapyramidal movement disorders, diseases of the neuromuscular junction and muscles, system atrophies mainly affecting the central nervous system, muscular dystrophies, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, motor neuron diseases represented by amyotrophic lateral sclerosis, abnormal involuntary movements, gait and movement disorders, ataxia, mitochondrial-related neuromusculoskeletal diseases, and sarcopenia.
4. 4. The pharmaceutical combination for use according to any one of claims 1 to 3, wherein the age-related and / or degenerative disease of the neuromusculoskeletal system is an extrapyramidal movement disorder, a disease of the neuromuscular junction and muscles, a system atrophy mainly affecting the central nervous system, muscular dystrophy, Duchenne muscular dystrophy, spinal muscular atrophy and related diseases, a motor neuron disease represented by amyotrophic lateral sclerosis, an abnormal involuntary movement, a gait and movement disorder, or an ataxia.
5. 4. The pharmaceutical combination for use according to claim 3, wherein the neuromusculoskeletal age-related and / or degenerative disease is sarcopenia.
6. 4. The pharmaceutical combination for use according to claim 3, wherein the age-related and / or degenerative disease of the neuromusculoskeletal system is a mitochondrial-associated neuromusculoskeletal disease or a mitochondrial-associated neuromusculoskeletal disease selected from central core disease and optic atrophy 1 (OPA1)-associated disease.
7. 2. The pharmaceutical combination for use according to claim 1, wherein the age-related inflammatory disease and / or degenerative inflammatory disease is a disease associated with increased cytokine levels.
8. The pharmaceutical combination for use according to claim 1, wherein the age-related endocrine metabolic disorder and / or degenerative endocrine metabolic disorder is obesity or sarcopenic obesity.
9. The pharmaceutical combination for use according to any one of claims 1 to 8, wherein the biguanide is metformin.
10. The pharmaceutical combination for use according to any one of claims 1 to 9, wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine.
11. 11. The pharmaceutical combination for use according to claim 10, wherein the acetylcholinesterase inhibitor is galantamine.
12. A pharmaceutical combination for the prevention, stabilization and / or reduction of age-related and / or degenerative complaints, said pharmaceutical combination comprising: a biguanide, or an N-oxide, hydrate, pharma- ceutically acceptable salt, or solvate thereof; an acetylcholinesterase inhibitor, or an N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof; A pharmaceutical combination comprising:
13. A pharmaceutical combination for improving an index of lifespan and / or healthspan, comprising: a biguanide, or an N-oxide, hydrate, pharma- ceutically acceptable salt, or solvate thereof; an acetylcholinesterase inhibitor, an N-oxide, a hydrate, a pharma- ceutically acceptable salt or a solvate thereof; Including, A pharmaceutical combination, wherein the improvement in indicators of lifespan and / or healthspan is selected from the group including improved function in age-related physical disabilities, stabilization of the worsening of age-related physical disabilities, reduction or stabilization of age-related complaints, reduction or stabilization of degenerative dysfunction and degenerative complaints relative to the subject's condition prior to administration of the pharmaceutical combination or relative to a control population.
14. 14. The pharmaceutical combination according to claim 12 or 13, wherein the age-related and / or degenerative complaints are selected from the group comprising muscle weakness, muscle loss, neuromuscular degeneration, movement disorders, impaired immune response, metabolic imbalance, generalized weakness.
15. 13. The pharmaceutical combination according to claim 12, wherein the age-related and / or degenerative complaints are selected from the group comprising muscle weakness, muscle loss, neuromuscular degeneration, and movement disorders.
16. 13. The pharmaceutical combination according to claim 12, wherein the age-related and / or degenerative complaint is a generalized feeling of weakness.
17. 14. The pharmaceutical combination of claim 13, wherein the improvement in indicators of lifespan and / or healthspan comprises improvement in one or more parameters selected from the group consisting of cholesterol levels, triglyceride levels, high density lipoprotein levels, low density lipoprotein levels, leptin levels, adiponectin levels, inflammatory parameters, and blood pressure, immunosenescence, and wherein the indicators of lifespan and / or healthspan are improved relative to the condition of the subject prior to administration of the pharmaceutical combination or relative to a control population.
18. The pharmaceutical combination according to any one of claims 12 to 17, wherein the biguanide is metformin.
19. The pharmaceutical combination according to any one of claims 12 to 18, wherein the acetylcholinesterase inhibitor is selected from the group comprising galantamine, donepezil, rivastigmine and memantine.
20. 20. The pharmaceutical combination of claim 19, wherein the acetylcholinesterase inhibitor is galantamine.
21. 21. The pharmaceutical combination for use according to any one of claims 1 to 11 or the pharmaceutical combination according to any one of claims 12 to 20, wherein the biguanide and the acetylcholinesterase inhibitor are administered to the subject in sub-therapeutic doses.
22. The pharmaceutical combination or pharmaceutical formulation for use according to any one of claims 1 to 21, wherein the subject is a human subject.
23. 23. The pharmaceutical combination or pharmaceutical combination for use according to any one of claims 1 to 22, wherein the biguanide and the acetylcholinesterase inhibitor, or the N-oxide, hydrate, pharma- ceutically acceptable salt or solvate thereof, are formulated in separate pharmaceutical compositions or are formulated in a single pharmaceutical composition.
